Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Crosstalk Ca2+ Signaling between Ryanodine Receptors Type 1 and 2 in the Pathogenesis of Cardiac Hypertrophy and Heart Failure

Award Number: R01HL164941
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2023
PERIOD OF PERFORMANCE END DATE: 03/31/2027

Group Awards By:

View Award Description

Crosstalk Ca2+ Signaling between Ryanodine Receptors Type 1 and 2 in the Pathogenesis of Cardiac Hypertrophy and Heart Failure - The underlying molecular mechanisms for heart failure (HF) are multifactorial, with energy dysregulation and oxidative stress appearing to be the key causes. The well-balanced energy consumption/generation of the working heart is thought to be achieved by Ca2+ entry via mitochondrial Ca2+ uniporter (MCU) which stimulates enzymes in the tricarboxylic acid (TCA) cycle for ATP generation, referred to as excitation-bioenergetics (EB) coupling. Surprisingly, knockout of MCU in the heart results in minimal defects in bioenergetics, suggesting that other Ca2+ transporters also may participate in EB coupling. We have previously shown that ryanodine receptor type 1 (RyR1) is expressed in cardiac mitochondria (mRyR1), playing a key role in EB coupling. Several groups have confirmed our findings, including recent reports showing that Ca2+ release from the sarcoplasmic reticulum (SR) is tunneled to mRyR to stimulate ATP production. We have also obtained new data showing that RyR1 expression is increased in mouse and human hypertrophied heart. The mitochondria isolated from RyR1 over expression (OE) mouse hearts have higher Ca2+ concentrations ([Ca2+]m) and increased ROS generation. This RyR1 OE mouse also shows cardiac hypertrophy and higher frequency of Ca2+ sparks, suggesting leakier RyR2 for Ca2+. Taken together, we propose a novel central hypothesis: Hypertrophic stimuli lead to mRyR1 overexpression in heart to compensate for increased energy demands by promoting mitochondrial Ca2+ uptake for EB coupling (Aim 1). However, chronic increases in mitochondrial Ca2+ uptake causes a sustained high level of ROS generation via Rieske iron-sulfur protein (RISP) at complex III (Aim 2). The increased ROS would oxidize and thus activate nearby SR RyR2 further increase mitochondrial Ca2+ loading due to constant Ca2+ leak from SR. This vicious cycle of ↑mRyR1→↑[Ca2+]m→↑ROS→↑SR RyR2 Ca2+ leak→↑[Ca2+]m (→: leads to, ↑: increases), which causes mitochondrial dysfunction including opening of mitochondrial permeability transition pore. Consequently, the heart is failing because of the inadequate energy for pumping and higher myocyte death and injury (Aim 3). The successful research outcome from this proposal will provide a new paradigm for HF: that RyR1 OE in the stressed heart is an initial adaptive mechanism that sequentially become mal-adaptive, which subsequently leads to HF. This new information will highlight a potentially innovative therapeutic strategy for development of novel inhibitors that are more selective for RyR1 than for RyR2 – such as dantrolene which has already been frequently used for treating malignant hyperthermia patients – as effective treatments of cardiac hypertrophy and HF.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $557,071 )
2026	2026	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Cardiovascular Diseases Research	000	4	3/23/2026	NON-COMPETING CONTINUATION	$557,071
														Subtotal = $557,071

Issue Date FY: 2025 ( Subtotal = $568,440 )
2025	2025	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Cardiovascular Diseases Research	001	3	6/4/2025	NON-COMPETING CONTINUATION	$56,844
2025	2025	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Cardiovascular Diseases Research	000	3	4/22/2025	NON-COMPETING CONTINUATION	$511,596
														Subtotal = $568,440

Issue Date FY: 2024 ( Subtotal = $557,071 )
2024	2024	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Cardiovascular Diseases Research	001	2	6/20/2024	NON-COMPETING CONTINUATION	$45,475
2024	2024	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Cardiovascular Diseases Research	000	2	3/8/2024	NON-COMPETING CONTINUATION	$511,596
														Subtotal = $557,071

Issue Date FY: 2023 ( Subtotal = $582,440 )
2023	2023	THOMAS JEFFERSON UNIVERSITY	1020 WALNUT ST STE 1	PHILADELPHIA	PA	19107	PHILADELPHIA	USA	Cardiovascular Diseases Research	000	1	3/9/2023	NEW	$582,440
														Subtotal = $582,440

Grand Total All Awards = $2,265,022

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Crosstalk Ca2+ Signaling between Ryanodine Receptors Type 1 and 2 in the Pathogenesis of Cardiac Hypertrophy and Heart Failure

Award Number: R01HL164941

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2023

PERIOD OF PERFORMANCE END DATE: 03/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer